Lv5
1190 积分 2023-03-20 加入
Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2– metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial
11天前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
A single droplet digital PCR for ESR1 activating mutations detection in plasma
2个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
4个月前
已完结
Multi-omic-based classification for identifying optimal neoadjuvant treatment strategies for high-risk early-stage breast cancer
6个月前
已完结
A systematic literature review of MTAP deletions in solid and hematologic Cancers
6个月前
已完结
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial
6个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
6个月前
已完结
A DNA‐Based Approach for the Forensic Identification of Asiatic Black Bear (Ursus thibetanus) in a Traditional Asian Medicine*
7个月前
已完结
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study
8个月前
已完结
皖公网安备34019202002308
